Premium
EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL
Author(s) -
Morschhauser F.,
Ghosh N.,
Lossos I.,
Palomba M.L.,
Mehta A.,
Casasnovas O.,
Stevens D.,
Chitra S.,
Knapp A.,
Nielsen T.,
Oestergaard M.,
Wenger M.,
Salles G.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.74_2629
Subject(s) - medicine , atezolizumab , obinutuzumab , lenalidomide , follicular lymphoma , oncology , phases of clinical research , regimen , gastroenterology , rituximab , clinical trial , lymphoma , cancer , multiple myeloma , immunotherapy , pembrolizumab